Both developing (Days --1-+12 relative to inoculation) and established (Days +18-+29) stages of Mycobacterium butyricum adjuvant-induced
polyarthritis in rats were treated orally with
cryogenine (100 mg/kg/day), a prototype anti-inflammatory (
phenylbutazone, 100 mg/kg/day), or a prototype immunosuppressive (
cyclophosphamide, 6 mg/kg/day). During developing
adjuvant arthritis,
cryogenine and
phenylbutazone significantly reduced the nonimmune-mediated
inflammation in the inoculated hindpaw. Neither
cryogenine nor
phenylbutazone provided protection against the development of the delayed-onset, immune-mediated
inflammation and the reduction in growth rate seen after Day +12 in unmedicated rats.
Cyclophosphamide failed to reduce the nonimmune-mediated
inflammation, but it provided significant protection against both the delayed-onset, immune-mediated
inflammation and the reduced growth rate. During established
adjuvant arthritis,
cryogenine and
phenylbutazone were effective against the established
inflammation, while
cyclophosphamide was ineffective. These results confirm the known anti-inflammatory and immunosuppressive activities of
phenylbutazone and
cyclophosphamide, respectively, and indicate that
cryogenine lacks immunosuppressive capability at the effective anti-inflammatory dosage level used.